Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602679 | 1.00 | CTSK (0.46) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL4768423 | 0.96 | CTSK (0.47) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL4768417 | 0.96 | CTSK (0.47) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL4635675 | 0.90 | CTSK (0.43) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL4635668 | 0.90 | CTSK (0.43) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL1411658 | 0.87 | CTSK (0.48) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL21571253 | 0.87 | CTSK (0.48) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL3004548 | 0.87 | CTSK (0.48) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL4632323 | 0.86 | CTSK (0.46) | CTSKHDAC4HDAC1HDAC6CTSS | |
| SCHEMBL4632325 | 0.86 | CTSK (0.46) | CTSKHDAC4HDAC1HDAC6CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915351-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | TP53, TP53BP1, ACIN1 | CTSK 1839/4885HDAC4 915/4885HDAC1 353/4885 |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | TP53, ACIN1, TP53BP1 | CTSK 1836/4885HDAC4 676/4885HDAC1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.